# PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105

> **NCT03278275** · PHASE2 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 116 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** One injection of 68Ga-NOTA-AE105
- **DEVICE:** PET/CT

## Key facts

- **NCT ID:** NCT03278275
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2021-07-08
- **Final completion:** 2021-07-08
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278275, "PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03278275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*